ADHD drug cardiac safety
FDA's Drug Safety & Risk Management Advisory Committee will discuss studies to assess the risk of adverse cardiovascular outcomes with drugs for attention deficit/hyperactivity disorder on Feb. 9. Adderall XR added warnings about cardiovascular events in certain patients in 2004 and the drug was suspended by Health Canada for several months in 2005. FDA has been looking at psychiatric and cardiovascular events across the entire category of ADHD drugs, which include J&J's Concerta, Novartis' Ritalin and Focalin, and Lilly's Strattera (1"The Pink Sheet" Oct. 3, 2005, p. 8). The meeting will take place at the Holiday Inn in Gaithersburg, Md., beginning at 8 a.m. [Editor's note: To 2watch a webcastor order a video/DVD of this and other meetings, visit FDAAdvisoryCommittee.com.]...
You may also be interested in...
FDA does not intend to release a general public health advisory for attention deficit/hyperactivity disorder medications despite issuing one for Lilly's Strattera (atomoxetine) Sept. 29
Ultragenyx enters a competitive and complicated market, but the combination of its manufacturing platform with Solid’s transgene could provide an advantage.
In this week’s podcast, Medtech Insight's managing editor Marion Webb has an update from the virtual HLTH panel discussions on telehealth and robotics. Deputy editor Reed Miller discusses trial results from Boston Scientific’s next-generation Accurate neo2 self-expanding aortic valve presented during the Transcatheter Cardiovascular Therapeutics (TCT) meeting.